Search results
Showing 106 to 120 of 163 results for infarction
Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)
Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.
View recommendations for IPG653Show all sections
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for IPG380Show all sections
Sections for IPG380
Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.
View recommendations for IPG777Show all sections
Transcatheter endovascular closure of perimembranous ventricular septal defect (IPG336)
Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.
View recommendations for IPG336Show all sections
Sections for IPG336
Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).
View recommendations for IPG245Show all sections
Sections for IPG245
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Clopidogrel, administered with aspirin, improves outcome after myocardial infarction. It is not known whether antiplatelet agents other...
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
having PCI, particularly for people with ST‑segment elevation myocardial infarction (STEMI). However, the summary of product...
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
In development [GID-TA11482] Expected publication date: TBC
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.